By Elias Schisgall

Shares of Enliven Therapeutics were sharply higher after the biotechnology company reported positive initial data from a Phase 1b trial for a leukemia treatment.

The stock was up 61% at $24.95 in Thursday morning trading. Shares have stayed roughly flat over the past year.

Enliven said the treatment, ELVN-001, had a cumulative major molecular response rate of 69% by 24 weeks among patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors.

Enliven Chief Medical Officer Helen Collins said the company is preparing to work with the Food and Drug Administration to initiate a Phase 3 trial in the second half of the year.

"We are excited about these initial Phase 1b data, the progress we made throughout 2025 and the year ahead," Collins said. "Our data continue to demonstrate that ELVN-001 has the potential to be the best-in-class active-site TKI for the treatment of CML and an important treatment option across all lines of therapy."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 08, 2026 10:03 ET (15:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.